Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of F61 Injection in Healthy Chinese Subjects
NCT05483504Phase 1Unknown
- Sponsor
- Wuhan Institute of Biological Products
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing F61 injection with F61 placebo (2 arms). Primary endpoints: Adverse Events at 105 days and Adverse Reactions at 105 days. Status: unknown.
02
Drugs
F61
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05483504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483504.